In Vivo Fluorescence Molecular Bronchoscopy of Durvalumab-680LT in Patients With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) After Chemoradiotherapy

NCT07653438 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Stage III Non-small Cell Lung Cancer
Unresectable Stage III NSCLC

Interventions

DRUG: Fluorescence molecular imaging during bronchoscopy with durvalumab-680LT

Sponsor

University Medical Center Groningen